Valuation: Inventiva

Market Cap 783M 904M 740M 672M 1.26B 86.71B 1.27B 8.84B 3.42B 43.98B 3.4B 3.32B 140B P/E 2026 *
-4.7x
P/E 2027 * -4.24x
Enterprise Value 733M 846M 693M 629M 1.18B 81.14B 1.19B 8.27B 3.2B 41.16B 3.18B 3.11B 131B EV / Sales 2026 *
144x
EV / Sales 2027 * 2.01x
Free-Float
89.08%
Yield 2026 *
-
Yield 2027 * -
1 day-3.49%
1 week-12.76%
Current month-18.15%
1 month-14.56%
3 months+5.74%
6 months-36.13%
Current year-15.97%
1 week 3.27
Extreme 3.27
3.74
1 month 3.27
Extreme 3.27
4.39
Current year 2.88
Extreme 2.88
6.2
1 year 2.88
Extreme 2.88
6.2
3 years 1.43
Extreme 1.434
6.2
5 years 1.43
Extreme 1.434
13.18
10 years 1.43
Extreme 1.434
16.3
Manager TitleAgeSince
Chief Executive Officer 53 2025-09-30
Director of Finance/CFO 59 2026-04-21
Chief Operating Officer - 2026-08-30
Director TitleAgeSince
Director/Board Member 76 2017-01-31
Director/Board Member 63 2019-05-26
Director/Board Member 52 2024-04-30
Date Insider Type Main position Quantity % Market Cap. Importance
1/10/26 Others

Executive/Senior Manager

50,000 0.0262%
1/10/26 Others

General Counsel

25,000 0.0131%
1/10/26 Others

Head of Human Resources

25,000 0.0131%
Change 5-day change 1-year change 3-year change Capi.($)
-3.49%-12.76%-24.83%-13.45% 937M
+0.66%+1.83%+47.32%+97.63% 69.18B
-1.19%-1.92%+34.57%+73.08% 62B
+2.22%-4.83%-15.32%+360.65% 26.19B
+1.42%+6.63%+29.14%+16.17% 25.75B
-0.89%-2.34%-3.46%-15.24% 24.29B
+2.84%+3.61%+24.60%-17.13% 19.84B
0.00%-10.41%+171.96%+298.75% 15.65B
-0.21%-2.66%+45.07%+160.34% 14.1B
+1.26%-1.69%-8.82%+461.93% 14.09B
Average +0.26%-3.25%+30.02%+142.27% 27.2B
Weighted average by Cap. +0.41%-1.29%+34.37%+124.51%

Financials

2026 *2027 *
Net sales 5.07M 5.85M 4.79M 4.35M 8.16M 562M 8.21M 57.24M 22.12M 285M 21.99M 21.5M 908M 108M 124M 102M 92.34M 173M 11.91B 174M 1.21B 469M 6.04B 466M 456M 19.26B
Net income -159M -183M -150M -136M -255M -17.56B -257M -1.79B -692M -8.91B -688M -672M -28.39B -104M -120M -98.38M -89.31M -167M -11.52B -168M -1.17B -454M -5.84B -451M -441M -18.63B
Net Debt -50.28M -58.02M -47.52M -43.14M -80.86M -5.57B -81.34M -567M -219M -2.82B -218M -213M -9B -567M -654M -536M -486M -912M -62.75B -917M -6.4B -2.47B -31.83B -2.46B -2.4B -101B
Logo Inventiva
Inventiva is a clinical-stage biopharmaceutical company focused on the research and development of oral small molecule therapies for the treatment of patients with MASH and other diseases with significant unmet medical need. The Company is currently evaluating lanifibranor, a novel pan-PPAR agonist, in the NATiV3 pivotal Phase 3 clinical trial for the treatment of adult patients with MASH, a common and progressive chronic liver disease. Inventiva owns an extensive library of approximately 240,000 pharmacologically relevant molecules, approximately 60% of which are proprietary, as well as a wholly owned research and development facility.
Employees
73
Date Price Change Volume
26-09-16 €3.315 -3.49% 269,859
26-09-15 €3.435 +0.88% 308,993
26-09-14 €3.405 +0.15% 521,767
26-09-11 €3.400 -7.48% 527,873
26-09-10 €3.675 -3.29% 250,162
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
-
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
6
Last Close Price
3.315EUR
Average target price
9.856EUR
Spread / Average Target
+197.32%

Quarterly revenue - Rate of surprise

LAST HOURS | 40% Discount: The Best Subscriber-Only Tools to Unlock Hidden Opportunities!
d
:
:
SEIZE THE OFFER!